These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 676458)

  • 21. Adjuvant combination immunotherapy (BCG and levamisole) in malignant melanoma.
    Dandapat MC; Mohapatra SK; Patra SK
    Indian J Cancer; 1985 Jun; 22(2):100-7. PubMed ID: 3842124
    [No Abstract]   [Full Text] [Related]  

  • 22. Adjuvant treatment of cancer. III. Malignant melanoma.
    Lundy J
    Conn Med; 1978 Apr; 42(4):220-2. PubMed ID: 639504
    [No Abstract]   [Full Text] [Related]  

  • 23. [Combined immunotherapy and cytostatic therapy in stage II and III malignant melanoma (proceedings)].
    Rundenstam CM
    Lakartidningen; 1978 Dec; 75(49):4568-9. PubMed ID: 723339
    [No Abstract]   [Full Text] [Related]  

  • 24. [Use of immunotherapy in the treatment of malignant melanoma of the skin].
    Kristensen E
    Ugeskr Laeger; 1976 Feb; 138(8):468-73. PubMed ID: 1258215
    [No Abstract]   [Full Text] [Related]  

  • 25. [Results in the use of immunochemotherapy in patients with cutaneous malignant melanoma].
    Calbo L; Gorgone S; Palmeri R; Salibra M; Melita P
    Chir Ital; 1983 Aug; 35(4):519-25. PubMed ID: 6680859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant immunostimulation in malignant melanoma with oral Bacille Calmette-Guérin.
    MacGregor AB; Falk RE; Landi S; Ambus U; Samuel ES; Langer B
    Can J Surg; 1977 Jan; 20(1):25-30. PubMed ID: 832200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunologic defects in melanoma patients: lack of effect of BCG therapy.
    Gersten MJ; Hadden EM; Kaplan MH; Pinsky CM; Armstrong D; Hadden JW
    Clin Bull; 1977; 7(2):63-9. PubMed ID: 902403
    [No Abstract]   [Full Text] [Related]  

  • 28. [Immunological aspects of melanoma].
    Sjögren H
    Lakartidningen; 1976 Feb; 73(7):528-30. PubMed ID: 1250045
    [No Abstract]   [Full Text] [Related]  

  • 29. [Current aspects of melanoma research. II. Immunotherapy].
    Wätzig V
    Dermatol Monatsschr; 1977 May; 163(5):359-66. PubMed ID: 881082
    [No Abstract]   [Full Text] [Related]  

  • 30. Immunoprophylaxis of malignant melanoma with systemic BCG: study of strain, dose, and schedule.
    Gutterman JU; Mavligit G; McBride C; Frei E; Hersh EM
    Natl Cancer Inst Monogr; 1973 Dec; 39():205-12. PubMed ID: 4595319
    [No Abstract]   [Full Text] [Related]  

  • 31. Immunotherapy of melanoma with BCG: two fatalities following intralesional injection.
    McKhann CF; Hendrickson CG; Spitler LE; Gunnarsson A; Banerjee D; Nelson WR
    Cancer; 1975 Feb; 35(2):514-20. PubMed ID: 234291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Immunoreactivity in patients with surgically removed melanoma in the course of BCG vaccination (author's transl)].
    Lochman I; Kyselá T; Machálek J; Lochmanová A; Beska F
    Cesk Dermatol; 1980; 55(6):372-7. PubMed ID: 7460040
    [No Abstract]   [Full Text] [Related]  

  • 33. Pneumonitis with oral bcg.
    Schapira DV; McPherson TA
    N Engl J Med; 1977 Feb; 296(7):397. PubMed ID: 834203
    [No Abstract]   [Full Text] [Related]  

  • 34. [Nonspecific immunostimulation and immunochemotherapy of melanomas].
    Israël L
    Rev Prat; 1975 Nov; 25(51):4063-4, 4067-8. PubMed ID: 1209147
    [No Abstract]   [Full Text] [Related]  

  • 35. [Cancer immunotherapy in dermatological view (author's transl)].
    Lübbe D; Gstöttner R
    Arch Geschwulstforsch; 1980; 50(2):182-5. PubMed ID: 7436703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Coincidence of melanoma growth and immune status? Virus antigens as a parameter (author's transl)].
    Weber G; zur Hausen H; Klughardt G; Galle K
    MMW Munch Med Wochenschr; 1981 Feb; 123(8):295-8. PubMed ID: 6261128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Activity of 2,4 dinitrochlorbenzene skin tests during the course of immunotherapy of malignant melanomas].
    Richter J; Duchková H; Kubíková M
    Cas Lek Cesk; 1975 Sep; 114(39):1201-3. PubMed ID: 1182748
    [No Abstract]   [Full Text] [Related]  

  • 38. Adjuvant BCG immunotherapy for stage I and II malignant melanoma.
    Silver HK; Ibrahim EM; Evers JA; Thomas JW; Murray RN; Spinelli JJ
    Can Med Assoc J; 1983 Jun; 128(11):1291-5. PubMed ID: 6342739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [BCG vaccination].
    Kosunen T
    Duodecim; 1974; 90(24):1709-11. PubMed ID: 4442342
    [No Abstract]   [Full Text] [Related]  

  • 40. Immunotherapy of patients with cancer.
    Smith GV; Morse PA; Deraps GD; Raju S; Hardy JD
    Surgery; 1973 Jul; 74(1):59-68. PubMed ID: 4715883
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.